A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma

NCT02529852 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

59

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: Lenalidomide
DRUG: Obinutuzumab
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Vincristine
DRUG: Prednisone

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]